Assembly Biosciences (ASMB) Common Equity (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly Common Equity of $198.6 million for Q1 2026, up 631.99% year-over-year from $27.1 million in Q1 2025, and down 3.94% quarter-over-quarter from $206.8 million in Q4 2025.
Assembly Biosciences (ASMB) Common Equity (2010 - 2026) Analysis & Trends
Assembly Biosciences' Common Equity history runs 17 years deep, the most recent figure standing at $198.6 million for Q1 2026.
- In Q1 2026, Common Equity rose 631.99% year-over-year to $198.6 million; the TTM figure through Mar 2026 stood at $198.6 million (up 631.99% YoY), while the FY2025 annual figure was $206.8 million, up 519.78% from the prior year.
- Common Equity for Q1 2026 stood at $198.6 million, down from $206.8 million in the prior quarter.
- The five-year high for Common Equity was $206.8 million in Q4 2025, with the low at $18.1 million in Q2 2025.
- The 5-year median for Common Equity is $54.9 million (2023), against an average of $83.8 million.
- The sharpest annual moves came in 2023 and 2026: Common Equity sank 59.27% in 2023, then surged 631.99% in 2026.
- Assembly Biosciences' Common Equity stood at $82.7 million in 2022, then tumbled by 50.28% to $41.1 million in 2023, then fell by 18.83% to $33.4 million in 2024, then surged by 519.78% to $206.8 million in 2025, then retreated by 3.94% to $198.6 million in 2026.
- Business Quant data shows ASMB's Common Equity at $198.6 million in Q1 2026, $206.8 million in Q4 2025, and $182.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | 305.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 305.65 Mn |
| Mar 31, 2026 | 198.61 Mn |
| Dec 31, 2025 | 206.75 Mn |
| Sep 30, 2025 | 182.70 Mn |
| Jun 30, 2025 | 18.10 Mn |
| Mar 31, 2025 | 27.13 Mn |
| Dec 31, 2024 | 33.36 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 34.68 Mn |
| Mar 31, 2024 | 32.60 Mn |
| Dec 31, 2023 | 41.10 Mn |
| Sep 30, 2023 | 41.71 Mn |
| Jun 30, 2023 | 54.95 Mn |
| Mar 31, 2023 | 70.33 Mn |
| Dec 31, 2022 | 82.66 Mn |
| Sep 30, 2022 | 102.40 Mn |
| Jun 30, 2022 | 123.98 Mn |
| Mar 31, 2022 | 146.79 Mn |
| Dec 31, 2021 | 168.93 Mn |
| Sep 30, 2021 | 224.65 Mn |